acut
respiratori
distress
syndrom
ard
heterogen
form
acut
diffus
lung
injuri
character
dysregul
inflamm
increas
alveolarcapillari
interfac
permeabl
noncardiogen
pulmonari
edema
gener
popul
incid
mortal
associ
ard
last
two
decad
steadili
declin
parallel
optim
approach
pneumonia
underli
caus
ard
well
increas
util
multimod
treatment
strategi
includ
lungprotect
ventil
cancer
set
signific
declin
incid
mortal
ard
also
report
although
rate
remain
significantli
higher
gener
popul
epidemiolog
studi
identifi
infect
includ
dissemin
fungal
pneumonia
major
underli
caus
ard
cancer
set
half
cancer
patient
develop
ard
surviv
hospit
discharg
surviv
often
face
protract
frequent
incomplet
recoveri
result
signific
longterm
physic
psycholog
cognit
sequela
residu
organ
dysfunct
poor
function
statu
ard
may
delay
preclud
subsequ
cancer
treatment
close
collabor
critic
care
physician
oncolog
team
essenti
identifi
revers
underli
caus
optim
treatment
cancer
patient
ard
asbaugh
colleagu
describ
adult
patient
develop
diffus
pulmonari
opac
refractori
hypoxemia
tachypnea
tachycardia
follow
acut
medic
ill
surgic
trauma
autopsi
promin
hyalin
membran
line
alveoli
seen
syndrom
initi
coin
adult
respiratori
distress
syndrom
later
renam
acut
respiratori
distress
syndrom
ard
emphas
acuiti
syndrom
includ
pediatricag
patient
similar
clinic
histopatholog
find
origin
definit
diagnosi
ard
establish
base
find
rapidli
progress
respiratori
failur
evolv
period
result
respiratori
distress
sever
arteri
hypoxemia
need
mechan
ventil
multipl
definit
ard
propos
sinc
origin
descript
asbaugh
americaneuropean
consensu
confer
aecc
expand
definit
includ
arteri
partial
pressur
oxygen
fraction
inspir
oxygen
mm
hg
bilater
infiltr
frontal
chest
radiograph
evid
left
atrial
hypertens
aecc
also
recogn
less
sever
form
ard
refer
acut
lung
injuri
ali
use
similar
ard
criteria
milder
hypoxemia
mm
hg
although
definit
ard
wide
adopt
criteria
lack
explicit
definit
acut
furthermor
interobserv
interpret
chest
radiograph
highli
variabl
ventil
set
peep
andor
render
ratio
inconsist
spur
issu
regard
lack
clear
definit
ard
expert
european
societi
intens
care
medicin
esicm
join
american
thorac
societi
at
societi
critic
care
medicin
sccm
empanel
creat
ard
definit
task
forc
meet
emerg
berlin
definit
ard
definit
defin
acut
atrisk
period
develop
ard
design
within
day
origin
insult
expert
also
propos
three
mutual
exclus
categori
ard
base
degre
hypoxemia
mild
mmhg
mmhg
moder
mmhg
sever
mmhg
panel
retain
requir
bilater
pulmonari
infiltr
consist
pulmonari
edema
defin
criteria
forard
ad
chest
comput
tomographi
ct
potenti
imag
tool
comparison
ard
definit
base
aecc
berlin
criteria
shown
tabl
expand
definit
ard
propos
murray
classifi
patient
accord
sever
lung
injuri
associ
clinic
disord
presenc
nonpulmonari
organ
dysfunct
definit
lung
injuri
sever
stratifi
accord
extent
abnorm
chest
radiograph
degre
hypoxemia
respiratori
system
complianc
peep
requir
use
lung
injuri
score
system
aliard
mark
three
sequenti
phase
character
differ
clinic
histopatholog
radiograph
manifest
acut
exud
phase
damag
pulmonari
epitheli
endotheli
surfac
trigger
cascad
event
evolut
aliard
loss
integr
epitheli
endotheli
barrier
ensu
result
extravas
proteinrich
edema
fluid
alveolar
space
form
increas
permeabl
pulmonari
edema
commonli
refer
primari
noncardiogen
pulmonari
edema
histopatholog
hallmark
accumul
proteinac
fluid
interstitium
result
breach
integr
alveolar
microvascular
barrier
within
lung
inflammatori
cell
includ
neutrophil
red
blood
cell
platelet
fibrin
also
promin
featur
edema
fluid
flood
alveoli
creat
larg
area
ventilationperfus
inequ
shunt
format
widespread
patchi
area
destruct
alveolar
type
epitheli
cell
exquisit
sensit
type
lung
injuri
common
earli
histolog
find
type
ii
pneumocyt
also
injur
result
disrupt
normal
epitheli
ion
transport
activ
reduc
surfact
turnov
consequ
reduc
clearanc
edema
fluid
airway
loss
normal
surfact
activ
activ
polymorphonuclear
neutrophil
plasma
protein
also
contribut
microatelectasi
shunt
format
impair
epitheli
cell
ion
transport
compound
effici
clearanc
edema
fluid
distal
airway
precipit
plasma
protein
fibrin
necrot
debri
form
hyalin
membran
hyalin
membran
along
mark
hyperplasia
cytolog
bizarr
pleomorph
type
ii
pneumocyt
key
compon
diffus
alveolar
damag
dad
histopatholog
hallmark
ard
physiolog
chang
promot
decreas
lung
complianc
subsequ
respiratori
failur
character
physiolog
sever
ventilationperfus
vq
mismatch
mark
refractori
hypoxemia
inhomogen
lung
injuri
pattern
mark
perfus
alveoli
adequ
ventil
physiolog
shunt
other
ventil
adequ
perfus
dead
space
increas
permeabl
pulmonari
edema
may
also
occur
absenc
dad
refer
capillari
leak
syndrom
cancer
set
type
pulmonari
edema
typic
occur
follow
administr
cytokin
tnf
disrupt
capillari
endotheli
cell
integr
drug
may
also
caus
direct
toxic
myocardium
result
mix
overlap
edema
associ
normal
increas
permeabl
etiolog
neurogen
reexpans
pulmonari
edema
repres
two
caus
mix
edema
frequent
observ
cancer
set
lung
injuri
may
resolv
exud
stage
progress
prolif
phase
final
stage
fibros
alveol
prolif
phase
ard
typic
occur
day
trigger
insult
phase
exuber
prolifer
type
ii
cell
fibroblast
inflammatori
cell
regener
epitheli
cell
occur
attempt
reestablish
alveolar
barrier
function
repair
damag
alveolar
structur
therapeut
measur
oxygen
toxic
may
promot
lung
injuri
phase
ard
prolif
phase
mark
minim
edema
fluid
abnorm
coagul
may
give
rise
extens
microvascular
microthrombi
disrupt
pulmonarycapillari
bed
subsequ
elev
pulmonari
vascular
resist
may
signific
enough
induc
cor
pulmonal
patient
extens
neutrophilpredomin
alveol
bal
fluid
histopatholog
find
bizarreshap
cuboid
type
ii
alveolar
cell
common
find
fever
leukocytosi
diminish
system
vascular
resist
diffus
area
alveolar
interstiti
consolid
chest
radiograph
may
mimic
clinic
infectionsepsi
phase
although
infecti
caus
rare
found
final
fibrot
phase
herald
extens
collagen
deposit
alveolar
vascular
interstiti
bed
irrevers
obliter
airspac
small
vessel
promot
dead
space
ventil
shunt
format
pulmonari
hypertens
refractori
hypoxemia
activ
innat
immun
respons
includ
neutrophil
complement
humor
inflammatori
mediat
thought
play
key
role
develop
dad
ard
lead
cascad
event
includ
product
tolllik
receptor
lung
epitheli
cell
activ
neutrophil
alveolar
macrophag
activ
alveolar
macrophag
trigger
addit
immun
respons
includ
cytokin
product
damag
alveolarcapillari
interfac
caus
leakag
proteinac
fluid
alveoli
lead
clinic
manifest
ard
earlier
studi
suggest
neutrophil
inflamm
central
develop
ard
howev
ard
may
develop
patient
profound
neutropenia
furthermor
stimul
neutrophil
product
granulocyt
colonystimul
factor
appear
trigger
worsen
ard
patient
observ
impli
neutrophil
inflamm
occur
consequ
rather
caus
ard
suggest
addit
mechan
acut
lung
injuri
may
import
role
proinflammatori
cytokin
initi
andor
amplif
inflammatori
respons
ard
suggest
increas
level
macrophag
inhibitori
factor
tumor
necrosi
factor
airway
patient
lung
injuri
antiinflammatori
activ
tumor
necrosi
factor
receptor
tnfr
receptor
antagonist
shown
modul
develop
aliard
alter
delic
balanc
pro
antiinflammatori
cytokin
airway
like
play
critic
role
aliard
develop
offer
therapeut
strategi
manag
disord
accumul
evid
increasingli
implic
platelet
activ
ard
pathogenesi
suggest
cell
pivot
host
inflammatori
effect
contribut
ard
develop
includ
increas
endotheli
barrier
permeabl
augment
neutrophil
recruit
airway
observ
laid
groundwork
ongo
studi
investig
role
antiplatelet
therapi
ard
major
patient
clinic
risk
factor
ard
develop
ard
thu
genet
suscept
thought
play
key
role
pathogenesi
disord
candid
gene
link
ard
risk
includ
gene
encod
angiotensinconvert
enzym
ace
tumor
necrosi
factor
tnf
vascular
endotheli
growth
factor
vegf
sever
molecular
immun
biomark
develop
identifi
distinct
ard
phenotyp
although
mani
biomark
current
experiment
stage
develop
hold
promis
potenti
risk
stratif
patient
ard
also
abil
predict
clinic
outcom
exampl
higher
plasma
level
inflammatori
biomark
demonstr
patient
hyperinflammatori
ard
phenotyp
subgroup
patient
may
higher
preval
sepsi
vasopressor
use
requir
longer
period
ventil
nonhyperinflammatori
counterpart
elev
level
specif
inflammatori
cytokin
shown
correl
lung
injuri
sever
may
predict
unfavor
outcom
particularli
among
patient
elev
biomark
occur
earli
persist
throughout
cours
ard
cancer
patient
suscept
varieti
overlap
ard
risk
factor
includ
primari
lung
insult
pneumonia
aspir
surgic
nonsurg
chest
andor
lung
trauma
secondari
sourc
injuri
drug
toxic
polytrauma
pancreat
hypertransfus
sepsi
septic
shock
origin
extrapulmonari
infect
noninfecti
etiolog
tabl
exampl
cancerrel
primari
insult
increas
suscept
pneumonia
propens
aspir
may
compound
varieti
malignancyrel
secondari
issu
includ
toxic
pneumotox
drug
bloodblood
product
transfus
sepsi
major
categori
risk
factorsthat
account
report
case
aliard
includ
infect
sepsi
chemotherapeut
agent
includ
molecular
target
therapi
immunemodul
agent
trauma
aspir
gastric
content
radiat
toxic
tumor
lysi
syndrom
leukoagglutinin
reaction
also
link
ard
patient
cancer
condit
may
act
synergist
increas
risk
aliard
studi
pepe
colleagu
ard
risk
increas
among
patient
three
risk
factor
versu
singl
risk
factor
versu
tradit
wide
held
belief
purport
specif
lung
injuri
trigger
bear
clinic
express
ard
diseas
progress
primarili
dictat
sever
lung
insult
efficaci
therapeut
intervent
recent
studi
question
valid
support
concept
suggest
clinic
histopatholog
featur
ard
ident
regardless
etiolog
investig
identifi
differenti
effect
ard
lung
complianc
respons
posit
endexpiratori
pressur
peep
sever
reduct
complianc
decreas
respons
peep
ventilatori
recruit
maneuv
prone
posit
adjunct
therapi
among
patient
primari
caus
ard
versu
extrapulmonari
secondari
etiolog
reduc
respiratori
complianc
respons
posit
endexpiratori
pressur
peep
may
correl
higher
preval
lung
consolid
patient
primari
ard
oppos
preval
edema
alveolar
collaps
associ
secondari
form
diseas
distinct
may
clinic
import
concept
ard
heterogen
disord
may
offer
precis
clinic
manag
howev
frequent
overlap
pathogenet
mechan
morpholog
alter
often
render
distinct
primari
secondari
form
ard
imprecis
concept
treatment
approach
base
etiolog
ard
remain
controversi
sever
ard
repres
classic
exampl
lung
failur
wherebi
associ
ventilationperfus
abnorm
shunt
alter
alveolarcapillari
diffus
lead
pure
hypoxia
least
earli
stage
contrast
primari
failur
alveolar
ventil
pump
failur
lead
sever
hypercapnia
acidosi
mild
hypoxemia
fig
impair
compon
ventilatori
pump
includ
respiratori
muscl
central
nervou
system
peripher
nervou
system
may
lead
pump
failur
cancer
treatment
may
advers
affect
compon
respiratori
pump
exampl
increas
resist
load
due
tumor
within
lung
may
caus
intrins
extrins
obstruct
larg
airway
bronchospasm
associ
certain
chemotherapeut
agent
concomit
copd
obstruct
sleep
apnea
associ
head
neck
tumor
common
caus
respiratori
compromis
patient
cancer
peripher
muscl
impair
owe
electrolyt
disturb
malnutrit
system
corticosteroid
eatonlambert
syndrom
chest
wall
diseas
may
also
occur
neurolog
myopath
chang
caus
chemo
immunotherapeut
agent
taxan
carboplatin
ipilimumab
nivolumab
well
describ
final
hypothyroid
brainstem
lesion
analges
sedat
medic
may
caus
profound
suppress
central
nervou
system
pump
failur
cancer
set
overlap
caus
lung
failur
pump
failur
often
coexist
result
intract
hypoxem
hypercarb
respiratori
failur
infect
respons
approxim
primari
secondari
caus
ard
cancer
set
tabl
pneumonia
common
potenti
lethal
form
infect
patient
cancer
complic
nearli
cancerrel
hospit
admiss
patient
hematolog
malign
hm
rate
pneumonia
may
exceed
lead
caus
death
particularli
set
hematopoiet
stem
cell
transplant
hsct
acut
leukemia
studi
azoulay
other
implic
pneumonia
underli
trigger
ard
patient
either
solid
hematolog
malign
compar
incid
pneumoniarel
ard
among
patient
without
cancer
opportunist
organ
includ
invas
aspergillu
pneumocysti
pneumonia
candidemia
promin
caus
primari
secondari
ard
cancer
account
case
cancerrel
cancer
treatmentrel
impair
immun
defens
larg
contribut
increas
vulner
patient
infect
account
disproportion
high
incid
ard
cancer
cytopenia
treatment
toxic
immun
derang
frequent
caus
recalcitr
pneumonia
particularli
among
patient
hematolog
malign
follow
hsct
bacteri
pneumonia
lead
caus
ard
set
opportunist
fungal
diseas
includ
invas
aspergillosi
pneumocysti
pneumonia
system
candidemia
increasingli
common
account
disproportion
percentag
pneumoniarel
ard
immunocompromis
patient
compar
incid
immunocompet
patient
ard
addit
profound
impair
cell
mediat
humor
immun
risk
factor
pneumonia
caus
reactiv
latent
viral
infect
cytomegaloviru
varicella
zoster
viru
herp
simplex
viru
infect
may
lead
ard
sequela
primari
pneumonia
dissemin
diseas
particularli
among
immunesuppress
hmhsct
patient
subgroup
hsct
patient
graftversushost
diseas
progress
upper
respiratori
tract
infect
includ
respiratori
syncyti
viru
influenza
parainfluenza
viru
lead
ard
may
also
occur
caus
increas
vulner
pneumonia
cancer
set
includ
derang
lung
architectur
caus
surgeri
radiat
cancer
prolong
mechan
ventil
swallow
difficulti
associ
thorac
tumor
pain
sedat
medic
final
repeat
exposur
antibiot
frequent
encount
healthcar
system
may
promot
develop
pneumonia
caus
multidrugresist
pathogen
establish
infect
may
exact
inexor
cours
high
associ
mortal
earli
etiolog
assess
initi
appropri
antimicrobi
therapi
along
prompt
initi
critic
care
vital
step
improv
outcom
gener
patient
popul
ard
thought
complic
case
sepsi
rate
sepsi
caus
aliard
cancer
set
thought
much
higher
although
true
incid
unknown
older
age
shock
pneumonia
pancreat
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
volum
fluid
resuscit
first
h
present
signific
risk
factor
among
septic
patient
ard
rate
sepsi
septic
shock
caus
gramneg
organ
well
bacteri
fungal
viral
pneumonia
vari
broadli
cancer
set
roughli
correl
degre
immun
suppress
estim
regard
incid
ard
attribut
chemotherapi
agent
imprecis
result
depend
heavili
individu
case
report
compet
diagnos
infect
may
occur
concomitantli
druginduc
ard
addit
mani
antineoplast
agent
prescrib
compon
complex
multidrug
multimod
regimen
render
identif
individu
drug
specif
culprit
difficult
although
nonspecif
pneumon
organ
pneumonia
frequent
histopatholog
find
druginduc
lung
injuri
acut
lung
injuri
dadard
report
small
percentag
patient
across
spectrum
antineoplast
therapi
includ
convent
cytotox
therapi
molecular
target
therapi
immunemodul
agent
high
supplement
oxygen
given
concurr
sequenti
concurr
granulocytecolonystimul
factor
granulocyt
macrophagecolonystimul
factor
gcsf
gmcsf
may
potenti
chemotherapyrel
ard
hyperoxia
increas
ard
risk
frequent
report
bleomycinexpos
patient
aliard
lead
caus
postop
respiratori
failur
mortal
rate
approach
gener
popul
mortal
rate
cancer
popul
vari
broadli
depend
type
cancer
surgeri
thorac
surgeri
particular
intrapericardi
extrapleur
pneumonectomi
esophagectomi
confer
highest
oper
risk
lung
injuri
fig
postop
acut
lung
injuri
set
often
due
pneumonia
pulmonari
edema
atelectasi
persist
air
leak
bronchopleur
fistula
prolong
mechan
depend
nosocomi
pneumonia
relat
acut
respiratori
failur
complic
approxim
thorac
upper
abdomin
cancer
surgeri
associ
mortal
rate
contribut
postop
ard
cancer
similar
gener
popul
includ
aspir
pneumon
massiv
transfus
shock
septic
hemorrhag
anaphylact
excess
periop
fluid
thorac
surgic
resect
involv
pneumonectomi
extend
surgic
manipul
singl
lung
ventil
inher
hyperoxia
volutrauma
also
confer
increas
risk
postop
ard
data
exist
regard
preval
lung
injuri
follow
lung
resect
recent
seri
suggest
around
patient
develop
degre
lung
injuri
develop
frank
ard
poor
prognosi
compar
suffer
lesser
degre
damag
pathogenesi
aliard
follow
intrathorac
resect
remain
unknown
periop
fluid
overload
increas
blood
flow
remain
lung
postop
reoxygen
injuri
activ
inflammatori
mediat
postul
possibl
caus
convent
paramet
preoper
assess
predict
patient
predispos
develop
lung
injuri
follow
lung
resect
hypoxia
diffus
interstiti
pulmonari
edema
may
occur
earli
h
follow
pneumonectomi
lobectomi
quickli
progress
respiratori
failur
rale
lung
examin
may
becom
clinic
appar
within
hour
present
mimick
ard
includ
pneumonia
pulmonari
embol
cardiogen
pulmonari
edema
pulmonari
embol
bronchopleur
fistula
format
exclud
posit
pressur
ventil
supplement
oxygen
fluid
restrict
diuret
repres
standard
care
set
although
postpneumonectomylobectomi
ard
inher
refractori
treatment
patient
succumb
ill
fig
increas
risk
ard
follow
cardiothorac
surgeri
tradit
associ
use
cardiopulmonari
bypass
cpb
need
blood
product
transfus
larg
volum
shift
mechan
ventil
direct
surgic
insult
impact
ard
cardiac
popul
substanti
affect
surviv
also
inhospit
length
stay
longterm
physic
psycholog
morbid
earli
identif
high
ard
risk
group
crucial
improv
postsurg
outcom
lung
injuri
follow
hematopoiet
stem
cell
transplant
hsct
occur
hsct
recipi
progress
ard
approxim
risk
factor
ard
set
includ
pneumonia
shock
sepsi
aspir
ard
frequent
versu
sever
occur
later
time
point
median
day
compar
day
among
recipi
allogen
transplant
versu
autolog
hsct
like
reflect
increas
vulner
infect
owe
intens
immun
suppress
among
allogen
recipi
surprisingli
posttranspl
outcom
among
group
patient
ard
poor
increas
icu
day
day
vs
day
among
autolog
recipi
higher
icu
mortal
transfusionrel
acut
lung
injuri
trali
transfusionrel
ard
distinct
clinic
condit
character
acut
lung
injuri
hypoxemia
mm
hg
fever
hypotens
cyanosi
bilater
pulmonari
infiltr
diagnosi
trali
requir
tempor
relationship
transfus
blood
product
develop
acut
lung
injuri
exclus
compet
risk
factor
ard
pneumonia
sepsi
pancreat
drug
toxic
trauma
grow
consensu
support
twohit
model
develop
trali
inflammatori
condit
infect
trauma
lung
lead
sequestr
prime
lung
neutrophil
subsequ
bloodblood
product
transfus
antibodi
endotoxin
store
blood
promot
endotheli
damag
induc
releas
oxidas
proteas
prime
neutrophil
sequenc
event
result
capillari
leak
acut
lung
injuri
although
precis
incid
trali
gener
popul
unknown
histor
estim
suggest
trali
develop
approxim
transfus
blood
compon
transfus
patient
trali
may
frequent
cancer
set
icu
suscept
patient
highest
consum
blood
blood
product
support
symptom
trali
typic
occur
earli
within
minut
initi
transfus
may
delay
h
follow
blood
product
administr
chest
imag
studi
demonstr
patchi
infiltr
unrel
cardiogen
pulmonari
edema
virtual
blood
product
includ
fresh
frozen
plasma
pack
red
blood
cell
prbc
platelet
granulocyt
cryoprecipit
intraven
immun
globulin
allogen
stem
cell
implic
develop
syndrom
specif
risk
factor
trali
may
stratifi
accord
recipi
factor
blood
product
factor
recipi
factor
includ
hematolog
malign
critic
ill
emerg
cardiac
surgeri
massiv
transfus
sepsi
mechan
ventil
high
apach
ii
score
gener
surgeri
cytokin
infus
activ
infect
also
link
trali
although
associ
confirm
blood
product
factor
includ
transfus
whole
blood
donor
gender
increas
rate
associ
increas
plasma
whole
blood
femal
donor
numer
studi
explor
influenc
rb
storag
time
transfusionrel
advers
event
includingtrali
posttransfus
infect
mix
result
recent
studi
suggest
transfus
fresh
day
old
rbc
confer
superior
transfus
outcom
standard
practic
transfus
blood
store
week
support
measur
includ
initi
supplement
oxygen
hemodynam
support
cornerston
trali
therapi
noninvas
respiratori
support
continu
posit
airway
pressur
cpap
indic
patient
mild
diseas
howev
approxim
patient
requir
invas
mechan
ventil
highdos
intraven
steroid
report
success
individu
case
report
although
prospect
trial
exist
exist
anecdot
evid
favor
use
steroid
manag
trali
limit
upon
suspicion
trali
transfus
immedi
discontinu
blood
bank
alert
possibl
transfus
reaction
recognit
alloimmun
pregnanc
render
multipar
women
highrisk
donor
develop
oftrali
nation
intern
riskreduct
strategi
implement
past
decad
exclud
multipar
women
donor
preferenti
util
male
nulligravida
donor
whole
blood
high
plasma
volum
compon
transfus
mitig
strategi
current
appli
platelet
red
blood
cell
product
due
concern
broader
applic
may
result
donor
shortag
platelet
red
blood
cell
product
riskreduct
strategi
includ
use
solventdetergenttr
plasma
stringent
screen
blood
blood
product
donor
also
implement
effort
result
signific
reduct
tralirel
incid
mortal
rate
prognosi
substanti
favor
compar
caus
acut
lung
injuri
mani
survivor
exhibit
full
recoveri
tumor
involv
pulmonari
vascular
bed
may
present
occlus
small
airway
tumor
microemboli
macrovascular
occlus
central
pulmonari
vessel
caus
larg
tumor
emboli
choriocarcinoma
tumor
mucin
origin
breast
lung
gastrointestin
tract
kidney
associ
highest
rate
tumor
embol
lymphangit
spread
tumor
frequent
accompani
tumor
microembol
howev
either
entiti
may
exist
isol
hyperleukocytosi
variabl
defin
wbc
greater
leukostasi
may
result
leukem
sequestr
leukocyt
thrombu
format
within
pulmonari
microvasculatur
disord
often
seen
among
patient
acut
chronic
myeloid
leukemia
blast
crisi
consid
oncolog
emerg
markedli
elev
poorli
deform
blast
cell
thought
plug
microcircul
lead
increas
blood
viscos
leukostasi
tissu
hypoperfus
cytokin
product
divid
blast
compound
problem
damag
endotheli
line
cell
result
alveolar
hemorrhag
patient
microvascular
thrombosi
typic
present
insidi
dri
cough
progress
dyspnea
hypoxemia
associ
echocardiograph
evid
pulmonari
hypertens
cor
pulmonal
interstiti
infiltr
suggest
lymphangit
spread
diseas
may
also
seen
prognosi
condit
type
malign
patient
acut
myeloid
leukemia
blast
crisi
tend
wors
evid
endorgan
damag
renal
neurolog
respiratori
treatment
leukostasi
hyperleukocytosi
includ
stabil
urgent
effort
reduc
wbc
count
cytoreduct
hydroxyurea
andor
leukapheresi
avoid
whole
blood
transfus
may
also
help
mitig
blood
hyperviscos
symptomat
hyerleukostasi
intraven
hydrat
correct
coagul
abnorm
includ
dissemin
intravascular
coagulopathi
aggress
platelet
support
mainstay
treatment
initi
chemotherapi
treatment
acut
nonlymphocyt
leukemia
report
precipit
acut
hypoxem
respiratori
failur
thought
caus
chemotherapyinduc
pulmonari
leukostasi
perivascular
hemorrhag
syndrom
known
leukem
cell
lysi
pneumopathi
report
follow
chemotherapi
acut
myelomonocyt
leukemia
patient
typic
present
within
initi
h
treatment
leukemia
sever
hypoxemia
associ
new
worsen
pulmonari
infiltr
chest
radiographi
lysi
leukem
cell
subsequ
releas
enzym
content
lead
diffus
alveolar
damag
ard
postul
mechan
lung
injuri
measur
may
artifici
low
patient
hyperleukocyt
leukemia
absenc
lung
involv
owe
leukocyt
metabol
oxygen
within
arteri
blood
ga
syring
set
oxygen
satur
obtain
puls
oximetri
normal
rapid
analysi
arteri
blood
ga
specimen
kept
ice
addit
cyanid
blood
ga
syring
effect
elimin
problem
patient
macrovascular
tumor
emboli
may
present
acut
onset
dyspnea
hypoxemia
pleurit
chest
pain
symptom
sign
close
resembl
acut
pulmonari
thromboembol
diseas
premortem
distinct
two
entiti
often
difficult
discern
microvascular
tumor
embol
howev
typic
present
insidi
symptom
dyspnea
nonproduct
cough
hypoxemia
sever
pulmonari
arteri
pressur
elev
cor
pulmonal
diffus
interstiti
infiltr
suggest
lymphangit
spread
diseas
common
find
heighten
alreadi
poor
prognosi
clinic
histopatholog
radiograph
manifest
aliard
highli
vari
acut
respiratori
failur
refractori
hypoxemia
typic
exud
stage
aliard
patient
commonli
develop
clinic
manifest
lung
injuri
earli
usual
within
h
exposur
injuri
agent
progress
respiratori
failur
need
noninvas
andor
invas
ventil
also
occur
earli
within
first
h
onset
patient
imag
find
vari
sever
ard
bilater
area
patchi
airspac
consolid
within
lung
peripheri
normal
cardiac
silhouett
absenc
kerley
b
line
classic
find
chest
radiograph
comput
tomographi
ct
alveolar
fill
consolid
within
depend
area
lung
also
characterist
find
may
appear
subtl
groundglass
opac
earli
stage
aliard
evolv
dens
consolid
chang
diseas
progress
imag
abnorm
may
close
mimic
cardiogen
edema
exclud
clinic
manifest
includ
progress
dyspnea
tachypnea
tachycardia
cough
diffus
rale
notori
nonspecif
find
diseas
progress
respiratori
distress
cyanosi
alter
mental
statu
chest
pain
owe
pneumothorax
case
may
occur
acut
hypoxemia
compensatori
respiratori
alkalosi
common
earli
derang
arteri
blood
gase
develop
hypercapn
respiratori
acidosi
signal
sever
diseas
impend
respiratori
failur
portend
poor
prognosi
goal
diagnost
evalu
ard
identifi
underli
caus
provid
guidanc
immedi
empir
treatment
earli
identif
treatment
caus
ard
shown
favor
impact
outcom
thu
evalu
relev
test
perform
earli
possibl
start
thorough
histori
clinic
examin
chest
imag
chest
radiograph
ct
imag
may
provid
critic
clue
diagnosi
help
exclud
compet
entiti
pneumonia
lobar
consolid
air
bronchogram
cavit
cardiogen
pulmonari
edema
presenc
kerley
b
line
cardiomegali
pulmonari
venou
congest
pleural
effus
diagnost
yield
bronchoscop
obtain
lavag
bal
fluid
cancer
set
vari
wide
may
help
evalu
infecti
etiolog
common
underli
infecti
trigger
ard
cancer
set
may
identifi
bal
fluid
includ
bacteria
invas
mycot
infect
tuberculosi
pneumocysti
viral
pathogen
addit
elev
eosinophil
bloodi
fluid
increas
hemosiderinladen
macrophag
malign
cell
bal
fluid
help
clue
diagnosi
acut
eosinophil
pneumonia
condit
diffus
alveolar
hemorrhag
lymphang
carcinomatosi
respect
util
lung
biopsi
set
debat
underli
trigger
ard
typic
identifi
use
less
invas
strategi
likelihood
obtain
addit
inform
care
weigh
overal
risk
surgic
procedur
nonetheless
surgic
biopsi
may
reason
specif
patholog
andor
revers
etiolog
lymphangit
spread
diseas
vascul
cryptogen
organ
pneumonia
suspect
obviou
less
invas
studi
surgic
obtain
biopsi
may
inform
critic
therapeut
prognost
decisionmak
complet
blood
count
cbc
coagul
studi
chemistri
liver
function
test
arteri
blood
ga
abg
analysi
includ
initi
blood
work
brain
natriuret
peptid
bnp
pron
termin
bnp
pront
bnp
troponin
level
may
help
exclud
cardiogen
caus
pulmonari
edema
serum
lipas
amylas
level
evalu
pancreat
investig
patient
abdomin
symptom
obviou
trigger
ard
laboratori
evid
organ
injuri
associ
hypoxemia
transamin
acut
renal
insuffici
frequent
find
advanc
diseas
metabol
acidosi
may
reflect
major
organ
site
involv
liver
kidney
sepsi
depend
clinic
suspicion
compon
ard
evalu
may
includ
nasopharyng
aspir
respiratori
viral
panel
urinari
antigen
cultur
legionella
streptococcu
pneumonia
pcr
pneumocysti
jirovecii
herp
simplex
viru
depend
underli
trigger
white
cell
count
may
elev
depress
normal
ard
consid
patient
develop
progress
dyspnea
hypoxia
bilater
pulmonari
infiltr
chest
imag
within
h
week
incit
event
unfortun
incit
event
frequent
unknown
earli
sign
symptom
often
miss
recoveri
death
may
occur
stage
ard
prognosi
primarili
depend
sever
chronic
treatment
ard
rather
etiolog
lung
injuri
survivorship
among
patient
progress
fibrot
phase
ard
mark
longterm
oxygen
depend
decreas
qualiti
life
condit
common
ard
infect
respiratori
failur
hemodynam
instabl
dissemin
intravascular
coagul
sepsi
gastrointestin
gi
bleed
independ
predict
variabl
presag
poor
outcom
assess
ill
sever
time
icu
admiss
use
sofa
sequenti
organ
failur
assess
score
also
help
identifi
highrisk
patient
predict
poor
outcom
although
treatment
ard
patient
cancer
similar
noncanc
set
uniqu
manifest
cancer
treatment
includ
increas
rate
neutropenia
infect
thrombocytopenia
mucos
thrombosi
repres
decis
challeng
highlight
ad
complex
manag
ard
cancer
patient
mortal
rate
excess
report
among
cancer
patient
requir
mechan
ventil
ard
past
highest
vulner
among
patient
hematolog
malign
recipi
hematopoiet
transplant
recent
investig
suggest
signific
declin
mortal
rate
offer
favor
perspect
tabl
surviv
gain
attribut
earli
identif
manag
precipit
condit
coupl
improv
prophylaxi
measur
infect
aspir
past
decad
addit
improv
hsct
techniqu
includ
aggress
use
hematopoiet
growth
factor
support
increas
use
donor
stem
cell
peripher
rather
bone
marrow
sourc
also
salutari
effect
ard
mortal
convinc
evid
also
shown
earlier
icu
transfer
within
h
onset
respiratori
symptom
also
associ
improv
surviv
final
expand
use
niv
lung
protect
strategi
attenu
ventilatorassoci
lung
injuri
central
improv
ventil
outcom
pulmonari
function
usual
may
return
normal
within
month
follow
mild
moder
ard
patient
sever
diseas
requir
prolong
ventilatori
support
may
develop
persist
abnorm
pulmonari
function
disabl
muscl
weak
neuropsychiatr
defici
studi
shown
benefici
impact
daili
interrupt
sedat
spontan
breath
trial
wake
breath
protocol
earli
mobil
mechan
ventil
patient
part
comprehens
multifacet
strategi
curtail
longterm
complic
ard
despit
extens
investig
evid
support
util
pharmacolog
therapi
adult
ard
manag
limit
random
control
trial
cohort
studi
suggest
highdos
glucocorticoid
may
offer
mortal
benefit
particularli
given
earli
fibroprolif
phase
ard
howev
consist
mortal
advantag
shown
furthermor
optim
steroid
dose
rang
mgkgday
mgkgday
variou
studi
establish
exogen
surfact
therapi
may
benefici
manag
childhood
ard
found
therapeut
util
adult
result
pharmacolog
investig
includ
ketoconazol
prostaglandin
prostacyclin
inhal
nitric
oxid
attenu
ard
risk
andor
improv
ard
outcom
equal
disappoint
respiratori
hemodynam
support
along
diuret
vasopressor
antibiot
indic
standard
support
care
measur
aliard
intraven
fluid
given
judici
care
attent
fluid
homeostasi
persist
posit
fluid
balanc
associ
increas
day
ventil
poor
clinic
outcom
thu
conserv
intraven
fluid
hydrat
titrat
lower
central
pressur
recommend
unless
contraind
prophylaxi
venou
thromboembol
use
lowmolecularweight
heparin
mg
enoxaparin
unit
subcutan
dalteparin
per
day
lowdos
unfraction
subcutan
heparin
unit
twice
daili
recommend
nonpharmacolog
measur
reduc
thrombu
risk
intermitt
pneumat
compress
ipc
consid
anticoagul
therapi
contraind
ipc
therapi
proven
benefit
reduc
dvt
postop
set
although
rigor
investig
devic
standalon
intervent
nonsurg
set
avail
patient
also
receiv
daili
stress
ulcer
prophylaxi
sucralf
ranitidin
omeprazol
unless
contraind
nutrit
support
initi
within
h
icu
transfer
prefer
enter
rout
accord
ada
guidelin
success
manag
ard
also
requir
expediti
evalu
treatment
nosocomi
communityacquir
pneumonia
secondari
infect
meticul
glycem
control
prevent
aspir
event
care
manag
gastrointestin
gi
bleed
also
frequent
issu
among
cancer
patient
ard
mandat
care
monitor
coordin
therapi
noninvas
ventil
niv
gain
broad
accept
manag
cancer
patient
respiratori
failur
base
pivot
random
control
studi
demonstr
unequivoc
efficaci
niv
manag
patient
pump
failur
well
select
case
lung
failur
recent
retrospect
studi
outcom
cancer
patient
follow
icu
transfer
arf
use
niv
associ
mark
improv
patient
surviv
addit
signific
reduct
icu
post
icu
hospit
mortal
link
use
intermitt
niv
earli
stage
hypoxem
arf
ratio
use
niv
also
associ
signific
declin
need
convent
mechan
ventil
howev
favor
result
may
appli
subset
patient
earli
stage
ard
interpret
caution
applic
niv
lungsaf
studi
associ
wors
mortal
investig
demonstr
improv
surviv
among
cancer
patient
ard
treat
niv
one
small
random
control
studi
immunocompromis
patient
hypoxem
acut
lung
injuri
initi
niv
result
improv
oxygen
reduc
need
endotrach
intub
howev
intub
associ
mortal
rate
control
group
suggest
surviv
gain
cancer
patient
ard
may
overestim
studi
demonstr
equal
high
mortal
rate
among
cancer
patient
fail
niv
subsequ
requir
mechan
ventil
nivmay
suffici
cancer
patient
mild
incipi
ard
mechan
ventil
reserv
patient
advanc
diseas
increas
niv
durat
steroid
therapi
organ
failur
includ
renal
failur
need
vasopressor
support
lack
definit
etiolog
trigger
ard
report
predictor
niv
failur
cancer
set
knowledg
determin
increas
risk
niv
failur
may
help
better
triag
patient
niv
versu
earli
intub
mechan
ventil
firstlin
ventil
support
patient
treat
niv
undergo
close
surveil
earli
sign
niv
failur
persist
hypoxemia
advanc
ard
endorgan
dysfunct
alter
mental
statu
signal
poor
niv
outcom
need
intub
mechan
ventil
mechan
ventil
cornerston
ard
treatment
pose
critic
conundrum
intervent
potenti
lifesav
time
potenti
deadli
abil
therapeut
intervent
potenti
lung
injuri
contribut
nonpulmonari
organ
failur
well
establish
increas
respiratori
drive
excess
pulmonari
dead
space
key
featur
ard
ard
progress
physiolog
derang
drive
minut
ventil
unsustain
level
result
progress
hypercapnia
goal
mechan
ventil
improv
oxygen
elimin
met
adjust
tidal
volum
drive
pressur
ga
flow
respiratori
rate
excess
adjust
paramet
may
result
ventilatorinduc
lung
injuri
vili
vili
manifest
clinic
volutrauma
excess
gener
mechan
stress
strain
lung
atelectrauma
injuri
caus
shear
forc
adjac
alveoli
collaps
reexpand
mechan
ventil
vili
tend
heterogen
injur
atelectat
area
adjac
rel
normal
aerat
area
ventil
strategi
past
util
larg
tidal
volum
mgkg
high
peep
cm
greater
effort
recruit
maintain
open
small
airway
lung
recruit
maneuv
entail
applic
high
airway
pressur
peep
variabl
durat
time
also
use
attempt
open
collaps
lung
unit
salutari
effect
increas
peep
improv
oxygen
mitig
atelectrauma
often
offset
attend
damag
consequ
high
alveolar
pressur
volum
advers
effect
high
pressur
strategi
aggrav
inhomogen
lung
damag
ard
caus
alveolar
unit
mechan
stress
other
convinc
evid
aggreg
studi
demonstr
increas
volutrauma
mortal
among
patient
sever
ard
strategi
appli
intent
mechan
ventil
rest
respiratori
muscl
maintain
adequ
ga
exchang
underli
caus
lung
injuri
treat
must
balanc
effort
mitig
deleteri
effect
vili
effort
achiev
goal
subject
mani
clinic
trial
recent
approach
advoc
lower
airway
pressur
offer
dual
benefit
minim
distens
aerat
area
mitig
trauma
repeat
open
close
alveoli
american
thorac
societi
at
european
societi
intens
care
medicin
esicm
societi
critic
care
medicin
sccm
met
analyz
evid
regard
use
ventilatori
strategi
establish
ardsnet
trial
key
recommend
emerg
meet
includ
lower
target
tidal
volum
mlkg
predict
bodi
weight
inspiratori
pressur
maintain
plateau
pressur
mm
low
tidal
volum
strategi
associ
rel
reduct
mortal
tidal
volum
maintain
mlkg
pbw
compar
mlkg
howev
strategi
limit
subsequ
hypercapnia
respiratori
acidosi
ard
progress
addit
attend
low
lung
volum
atelectasi
contribut
increas
pulmonari
vascular
resist
util
extracorpor
carbon
dioxid
ga
exchang
devic
venoven
extracorpor
membran
oxygen
vv
ecmo
remov
carbon
dioxid
studi
promis
result
although
strategi
remain
experiment
investig
probe
util
ecmo
vv
ecmo
systemat
exclud
cancer
patient
less
life
expect
mani
larger
clinic
trial
thu
even
less
known
regard
util
invas
mechan
devic
patient
ard
cancer
set
at
esicm
sccm
also
recommend
prone
posit
approach
promot
uniform
distribut
mechan
forc
throughout
injur
lung
therebi
facilit
homogen
lung
inflat
result
improv
oxygen
reduc
vili
adopt
prone
posit
adjunct
therapi
ard
stall
mani
year
base
earli
clinic
trial
demonstr
improv
oxygen
surviv
gain
intervent
observ
coupl
concern
regard
possibl
advers
event
prone
patient
includ
facial
edema
pressur
necrosi
skin
breakdown
transient
desatur
hemodynam
instabl
dislodg
line
endotrach
tube
lead
sporad
use
treatment
modal
year
howev
find
patient
metaanalysi
four
major
clinic
studi
well
proseva
trial
clearli
demonstr
mortal
benefit
prone
posit
among
subgroup
patient
sever
ard
base
observ
prone
posit
patient
sever
ard
recommend
recommend
strongli
endors
major
critic
care
thorac
societi
mark
major
shift
advis
care
ard
prone
posit
minimum
h
per
day
recommend
patient
sever
ard
pf
ratio
also
recommend
theoret
concept
behind
highfrequ
oscillatori
ventil
hfov
use
small
tidal
volum
oscil
high
mean
pressur
improv
ardsrel
mortal
result
mitig
effect
volutrauma
atelectrauma
howev
two
larg
clinic
trial
fail
discern
mortal
advantag
use
ventil
strategi
fact
oscil
trial
compar
ard
outcom
among
patient
undergo
earli
applic
ofhfov
patientsundergo
low
tidal
volumehigh
peep
ventil
strategi
discontinu
prematur
due
safeti
concern
includ
hemodynam
issu
higher
mortal
thu
studi
support
use
hfov
patient
ard
except
perhap
patient
sever
ard
pf
ratio
mmhg
although
research
need
past
three
decad
wit
prolifer
newer
mode
assist
mechan
ventil
includ
airway
pressur
releas
ventil
aprv
proport
assist
ventil
pav
mandatori
minut
ventil
mmv
neural
adjust
ventilatori
assist
nava
adapt
support
ventil
asv
smartcar
convent
volumepressur
open
loop
ventil
strategi
deliv
paramet
fix
lack
abil
integr
patient
feedback
adjust
ventil
set
newer
closedloop
ventil
strategi
design
adjust
ventil
set
base
patient
feedback
therebi
optim
patientventil
synchroni
improv
patient
safeti
comfort
mitig
work
breath
earlier
liber
ventil
also
facilit
closedloop
ventil
strategi
howev
longterm
studi
need
prove
efficaci
defin
true
advantag
benefit
compar
convent
ventil
strategi
particularli
relat
mechan
ventil
patient
ard
sedat
neuromuscular
blockad
import
compon
strategi
aim
optim
patientventil
interact
minim
patient
discomfort
agit
ventil
neuromuscularblock
agent
nba
indic
asynchroni
persist
despit
sedat
ventil
adjust
prescrib
earli
cours
ard
agent
may
reduc
vili
sever
pathophysiolog
mechan
paralyt
agent
elimin
patientiniti
doubl
trigger
ensur
deliveri
low
tidal
volum
addit
atelectrauma
reduc
elimin
activ
exhal
loss
peep
final
high
ventil
demand
hypercapniaassoci
escal
respiratori
drive
intrins
sever
lung
injuri
mitig
benefit
may
translat
favor
surviv
least
one
studi
demonstr
surviv
gain
among
nbatreat
patient
sever
ard
pf
ratio
compar
nonparalyz
control
past
two
decad
aliard
definit
crystal
ard
increasingli
recogn
heterogen
condit
fuel
varieti
trigger
specif
trigger
accept
import
contributor
uniqu
ard
phenotyp
well
prognosi
respons
treatment
thu
earli
aggress
revers
incit
event
pertin
special
treatment
option
includ
ventil
strategi
support
measur
furthermor
recognit
differ
ard
phenotyp
may
assist
develop
person
ventil
strategi
consid
patient
uniqu
physiolog
therebi
mitig
vili
improv
ard
outcom
recent
decad
wit
pivot
advanc
evidencebas
ard
treatment
strategi
advanc
result
signific
overal
improv
ard
mortal
gener
popul
surviv
gain
larg
attribut
optim
approach
pneumonia
underli
caus
ard
well
increas
util
multimod
treatment
strategi
includ
lungprotect
ventil
ard
prognosi
among
ventil
patient
cancer
set
evolv
dismal
encourag
although
mortal
rate
remain
high
uniqu
vulner
cancer
patient
respiratori
complic
caus
cancer
infect
toxic
effect
cancer
therapi
immun
suppress
cancer
treatmentrel
cytopenia
frequent
contribut
sever
lung
injuri
result
delay
oftentim
discontinu
cancer
therapi
moreov
longterm
morbid
decreas
qualiti
life
among
cancer
survivor
may
substanti
propens
sever
manifest
ard
present
niv
may
best
option
mani
cancer
patient
acut
lung
injuri
prognosi
follow
transit
mechan
ventil
follow
niv
failur
remain
bleak
consider
underscor
urgent
need
upfront
convers
patient
famili
member
togeth
oncologist
icu
team
effort
design
realist
critic
care
treatment
plan
avoid
therapeut
intransig
simultan
consid
patient
wish
life
expect
treatment
strategi
ard
cancer
set
larg
extrapol
investig
focu
ard
gener
popul
studi
focu
uniqu
challeng
cancer
patient
ard
urgent
need
